Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
M Wathikthinnakon, P Luangwattananun… - Scientific Reports, 2022 - nature.com
Cholangiocarcinoma (CCA) is a lethal cancer with rapid progression and poor survival.
Novel and more effective therapies than those currently available are, therefore, urgently …
Novel and more effective therapies than those currently available are, therefore, urgently …
Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
J Chen, Z Amoozgar, X Liu, S Aoki, Z Liu, SM Shin… - Cancer Immunology …, 2024 - AACR
Intrahepatic cholangiocarcinoma (ICC) has limited therapeutic options and a dismal
prognosis. Adding blockade of the anti–programmed cell death protein (PD)-1 pathway to …
prognosis. Adding blockade of the anti–programmed cell death protein (PD)-1 pathway to …
Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma
E Loeuillard, J Yang, ELN Buckarma… - The Journal of …, 2020 - Am Soc Clin Investig
Immune checkpoint blockade (ICB) has revolutionized cancer therapeutics. Desmoplastic
malignancies, such as cholangiocarcinoma (CCA), have an abundant tumor immune …
malignancies, such as cholangiocarcinoma (CCA), have an abundant tumor immune …
Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic …
JC Lu, LL Wu, YN Sun, XY Huang, C Gao… - Nature …, 2024 - nature.com
Intratumoral immune status influences tumor therapeutic response, but it remains largely
unclear how the status determines therapies for patients with intrahepatic …
unclear how the status determines therapies for patients with intrahepatic …
Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules
G Zhou, D Sprengers, S Mancham, R Erkens… - Journal of …, 2019 - Elsevier
Background & Aims Cholangiocarcinoma is an aggressive hepatobiliary malignancy
originating from biliary tract epithelium. Whether cholangiocarcinoma is responsive to …
originating from biliary tract epithelium. Whether cholangiocarcinoma is responsive to …
Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses
Y Zhu, XY Wang, Y Zhang, D Xu, J Dong… - Cancer management …, 2018 - Taylor & Francis
Background Agents targeting the programmed death ligand 1 (PD-L1)/programmed death
receptor 1 immune checkpoint exhibited promising clinical outcomes in a variety of …
receptor 1 immune checkpoint exhibited promising clinical outcomes in a variety of …
[HTML][HTML] Anti–PD-1 in combination with trametinib suppresses tumor growth and improves survival of intrahepatic cholangiocarcinoma in mice
Background & Aims Intrahepatic cholangiocarcinoma (iCCA) accounts for a fraction of
primary liver cancers but has a 5-year survival rate of only 10%. Immune checkpoint …
primary liver cancers but has a 5-year survival rate of only 10%. Immune checkpoint …
[HTML][HTML] Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma
S Hua, X Gu, H Jin, X Zhang, Q Liu, J Yang - Biomedicine & …, 2024 - Elsevier
Cholangiocarcinoma (CCA) is becoming more common and deadly worldwide. Tumor-
infiltrating T cell subtypes make distinct contributions to the immune system; collectively, they …
infiltrating T cell subtypes make distinct contributions to the immune system; collectively, they …
Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: possible immunotherapy …
F Yu, L Gong, Z Mo, W Wang, M Wu, J Yang… - Bioscience …, 2019 - jstage.jst.go.jp
Immunotherapy might be an effective treatment in extrahepatic cholangiocarcinoma (eCCA),
a tumor with extremely limited therapeutic options. Our study is to characterize the …
a tumor with extremely limited therapeutic options. Our study is to characterize the …
Mobilization and activation of tumor-infiltrating dendritic cells inhibits lymph node metastasis in intrahepatic cholangiocarcinoma
BY Sun, ZT Wang, KZ Chen, Y Song, JF Wu… - Cell Death …, 2024 - nature.com
Lymph node metastasis (LNM) facilitates distant tumor colonization and leads to the high
mortality in patients with intrahepatic cholangiocarcinoma (ICC). However, it remains elusive …
mortality in patients with intrahepatic cholangiocarcinoma (ICC). However, it remains elusive …
相关搜索
- cytotoxic activity cholangiocarcinoma cells
- intrahepatic cholangiocarcinoma pd l1
- lymphocyte cytotoxicity combination gemcitabine
- combination gemcitabine cholangiocarcinoma cells
- effector t lymphocytes cholangiocarcinoma cells
- combination with trametinib pd 1
- switch receptor cholangiocarcinoma cells
- intrahepatic cholangiocarcinoma cells exhaustion
- cells exhaustion gemcitabine oxaliplatin
- intrahepatic cholangiocarcinoma combination with trametinib
- intrahepatic cholangiocarcinoma gemcitabine oxaliplatin
- cytotoxic activity effector t lymphocytes
- ctla 4 pd l1
- tumor growth pd 1
- tumor microenvironment pd l1
- lymphocyte cytotoxicity cholangiocarcinoma cells